ImpriMed Expands AI Technology into Human Oncology

ImpriMed, a California-based startup, is expanding its AI technology from veterinary oncology to human oncology applications, aiming to improve treatment outcomes for dogs and cats with cancer. Recent funding of $23 million in Series A led by SoftBank Ventures Asia, with participation from strategic investor SK Telecom and other financial investors, will support the development of AI-powered drug efficacy prediction services. ImpriMed plans to partner with SK Telecom to develop AI-based veterinary X-ray image diagnosis technology, and aims to commercialize its AI software for multiple myeloma and offer live-cell-based drug sensitivity tests for human precision oncology. The company also plans to expand its workforce and broaden its pipelines in business development.